 WATERTOWN, Mass.--BUSINESS WIRE--Forma Therapeutics Holdings, Inc. Nasdaq: FMTX a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced new data from its ongoing Phase 1 trial of etavopivat formerly referred to as FT-4202 being presented at the 26th Annual European Hematology Association EHA 2021 Virtual Congress. The e-poster presentation includes initial data from the open-label extension OLE cohort showing etavopivat improved and 